The Experts below are selected from a list of 81 Experts worldwide ranked by ideXlab platform
R. Gupta - One of the best experts on this subject based on the ideXlab platform.
-
Clinical validation of Aneroid Sphygmomanometer.
Indian journal of physiology and pharmacology, 2012Co-Authors: Y Saxena, V Saxena, R. GuptaAbstract:Recent concerns about the mercury toxicity and its ill effects on the environment and health has led to widespread use of Aneroid manometers. Present study was conducted to analyse whether this change would lead to any systematic shift in measured blood pressure or consistency of blood pressure measurement in clinical setting. The clinical accuracy of the Welch Allyn Aneroid Sphygmomanometer model 7670-04 was studied against the mercury Sphygmomanometer on 83 volunteers from Dehradun. Two blood pressure reading of each study subject was recorded with pretested instruments (Aneroid and mercury Sphygmomanometer). Data analysis showed the difference of means between the reading of two devices against mean of the observer reading for both systolic (-3.62 +/- 4.88) and diastolic (-2.36 +/- 3.77) blood pressure were not statistically different. The corresponding values of the SBP and DBP from both the instruments showed significant correlation. Regression analysis of mercury versus Aneroid showed regression line (Y = 9.52 + 0.95X for SBP, Y = 0.36 + 0.96X for DBP) significantly different from line of equality (P < 0.001). The study has demonstrated that the Aneroid device (model: 7670-04) achieved grade B performance according to the British Hypertensive Society criteria.
-
SP4-21 Clinical validation of Aneroid Sphygmomanometer
Journal of Epidemiology and Community Health, 2011Co-Authors: Y Saxena, V Saxena, R. GuptaAbstract:Introduction The Mercury Sphygmomanometer has been used for more than 100 years to measure blood pressure. There are increasing concerns regarding mercury toxicity and its effects on the human health and the environment. Non-mercurial Aneroid Sphygmomanometers have flooded the market, although very few complying with standards. The aim of this study was to determine whether conversion to Aneroid manometers would cause a systematic shift in measured blood pressure. This study is important in ensuring the quality and consistency of blood pressure measurements taken across hospital clinics. Methods We examined 83 volunteers who were residents of Dehradun. Two blood pressure readings were taken by a trained observer for each volunteer using the Aneroid and mercury Sphygmomanometers randomly. The instruments were subjected to grading using the criteria from the British Hypertensive Society. Results There was no statistically significant difference in the mean systolic (−3.62±4.88) or diastolic (−2.36±3.77) blood pressure measurements obtained by either Sphygmomanometer. The values of the SBP and DBP from both the instruments showed a linear correlation with systolic blood pressure (SBP r=0.94***; DBP r=0.92***). Conclusions The study has demonstrated that the Aneroid device achieved a grade of B performance according to the criteria described by the British Hypertensive society, when used at clinical settings.
Y Saxena - One of the best experts on this subject based on the ideXlab platform.
-
Clinical validation of Aneroid Sphygmomanometer.
Indian journal of physiology and pharmacology, 2012Co-Authors: Y Saxena, V Saxena, R. GuptaAbstract:Recent concerns about the mercury toxicity and its ill effects on the environment and health has led to widespread use of Aneroid manometers. Present study was conducted to analyse whether this change would lead to any systematic shift in measured blood pressure or consistency of blood pressure measurement in clinical setting. The clinical accuracy of the Welch Allyn Aneroid Sphygmomanometer model 7670-04 was studied against the mercury Sphygmomanometer on 83 volunteers from Dehradun. Two blood pressure reading of each study subject was recorded with pretested instruments (Aneroid and mercury Sphygmomanometer). Data analysis showed the difference of means between the reading of two devices against mean of the observer reading for both systolic (-3.62 +/- 4.88) and diastolic (-2.36 +/- 3.77) blood pressure were not statistically different. The corresponding values of the SBP and DBP from both the instruments showed significant correlation. Regression analysis of mercury versus Aneroid showed regression line (Y = 9.52 + 0.95X for SBP, Y = 0.36 + 0.96X for DBP) significantly different from line of equality (P < 0.001). The study has demonstrated that the Aneroid device (model: 7670-04) achieved grade B performance according to the British Hypertensive Society criteria.
-
SP4-21 Clinical validation of Aneroid Sphygmomanometer
Journal of Epidemiology and Community Health, 2011Co-Authors: Y Saxena, V Saxena, R. GuptaAbstract:Introduction The Mercury Sphygmomanometer has been used for more than 100 years to measure blood pressure. There are increasing concerns regarding mercury toxicity and its effects on the human health and the environment. Non-mercurial Aneroid Sphygmomanometers have flooded the market, although very few complying with standards. The aim of this study was to determine whether conversion to Aneroid manometers would cause a systematic shift in measured blood pressure. This study is important in ensuring the quality and consistency of blood pressure measurements taken across hospital clinics. Methods We examined 83 volunteers who were residents of Dehradun. Two blood pressure readings were taken by a trained observer for each volunteer using the Aneroid and mercury Sphygmomanometers randomly. The instruments were subjected to grading using the criteria from the British Hypertensive Society. Results There was no statistically significant difference in the mean systolic (−3.62±4.88) or diastolic (−2.36±3.77) blood pressure measurements obtained by either Sphygmomanometer. The values of the SBP and DBP from both the instruments showed a linear correlation with systolic blood pressure (SBP r=0.94***; DBP r=0.92***). Conclusions The study has demonstrated that the Aneroid device achieved a grade of B performance according to the criteria described by the British Hypertensive society, when used at clinical settings.
V Saxena - One of the best experts on this subject based on the ideXlab platform.
-
Clinical validation of Aneroid Sphygmomanometer.
Indian journal of physiology and pharmacology, 2012Co-Authors: Y Saxena, V Saxena, R. GuptaAbstract:Recent concerns about the mercury toxicity and its ill effects on the environment and health has led to widespread use of Aneroid manometers. Present study was conducted to analyse whether this change would lead to any systematic shift in measured blood pressure or consistency of blood pressure measurement in clinical setting. The clinical accuracy of the Welch Allyn Aneroid Sphygmomanometer model 7670-04 was studied against the mercury Sphygmomanometer on 83 volunteers from Dehradun. Two blood pressure reading of each study subject was recorded with pretested instruments (Aneroid and mercury Sphygmomanometer). Data analysis showed the difference of means between the reading of two devices against mean of the observer reading for both systolic (-3.62 +/- 4.88) and diastolic (-2.36 +/- 3.77) blood pressure were not statistically different. The corresponding values of the SBP and DBP from both the instruments showed significant correlation. Regression analysis of mercury versus Aneroid showed regression line (Y = 9.52 + 0.95X for SBP, Y = 0.36 + 0.96X for DBP) significantly different from line of equality (P < 0.001). The study has demonstrated that the Aneroid device (model: 7670-04) achieved grade B performance according to the British Hypertensive Society criteria.
-
SP4-21 Clinical validation of Aneroid Sphygmomanometer
Journal of Epidemiology and Community Health, 2011Co-Authors: Y Saxena, V Saxena, R. GuptaAbstract:Introduction The Mercury Sphygmomanometer has been used for more than 100 years to measure blood pressure. There are increasing concerns regarding mercury toxicity and its effects on the human health and the environment. Non-mercurial Aneroid Sphygmomanometers have flooded the market, although very few complying with standards. The aim of this study was to determine whether conversion to Aneroid manometers would cause a systematic shift in measured blood pressure. This study is important in ensuring the quality and consistency of blood pressure measurements taken across hospital clinics. Methods We examined 83 volunteers who were residents of Dehradun. Two blood pressure readings were taken by a trained observer for each volunteer using the Aneroid and mercury Sphygmomanometers randomly. The instruments were subjected to grading using the criteria from the British Hypertensive Society. Results There was no statistically significant difference in the mean systolic (−3.62±4.88) or diastolic (−2.36±3.77) blood pressure measurements obtained by either Sphygmomanometer. The values of the SBP and DBP from both the instruments showed a linear correlation with systolic blood pressure (SBP r=0.94***; DBP r=0.92***). Conclusions The study has demonstrated that the Aneroid device achieved a grade of B performance according to the criteria described by the British Hypertensive society, when used at clinical settings.
Ronald J Prineas - One of the best experts on this subject based on the ideXlab platform.
-
assessing blood pressure accuracy of an Aneroid Sphygmomanometer in a national survey environment
American Journal of Hypertension, 2011Co-Authors: Yechiam Ostchega, Ronald J Prineas, Tatiana Nwankwo, George ZipfAbstract:BACKGROUND: The "gold standard" employed for obtaining blood pressure (BP) for all the National Health and Nutrition Examination Surveys (NHANES) has been the mercury Sphygmomanometer (HgS). Because of environmental concerns, there is a need to explore an alternative to HgS. METHODS: We compared the accuracy of the Welch Allyn 767 wall Aneroid Sphygmomanometer (AnS) to the HgS in children and adults and by BP cuff sizes. Each participant had three BP measurements per device recorded sequentially. The order of the devices and observer were random. A total of 727 individuals participating in the NHANES participated in the study. RESULTS: The mean AnS readings were not statistically significantly different from those of the HgS with the exception of systolic BP (SBP) in aged 8-17 years (mean difference 1.10, s.d. 4.87). There were no statistically significantly different by BP cuff sizes. Agreement for the prevalence of hypertension (BP ≥140 systolic or diastolic ≥90 mm Hg) was above chance (κ = 0. 81; sensitivity = 81%; specificity = 98%) with AnS readings underestimating by 1.66% (18.33 vs. 20%, P > 0.05) compared to the HgS reading. CONCLUSIONS: With the exception of SBP in ages 8-17 years, the AnS device readings were not significantly different from HgS readings by age or BP cuff sizes selection. Agreement for hypertension classification is good. An accurate and well-calibrated AnS could therefore provide an acceptable alternative to the use of a HgS in surveys, although with appropriate caution given the 81% sensitivity with regard to hypertension thresholds that was observed.
-
evaluating the accuracy of an Aneroid Sphygmomanometer in a clinical trial setting
American Journal of Hypertension, 2009Co-Authors: Marinella Temprosa, Ronald J Prineas, Sarah E Fowle, Maria G Montez, Jane Ownfriday, Mary Lou Carrionpeterse, Tracy WhittingtoAbstract:The mercury Sphygmomanometer has historically served as the “gold” standard for measurement of blood pressure. Recently, because of environmental concerns about the disposal of mercury-contaminated medical waste and the risk of spills from mercury Sphygmomanometers, the mercury Sphygmomanometer is being phased out in clinical settings. In 1998, the Environmental Protection Agency and American Hospital Association agreed to eliminate mercury containing waste from the health-care industry by 2005 (ref. 1). In response, many institutions began switching from mercury to Aneroid Sphygmomanometers. The Diabetes Prevention Program was a controlled, multi-center clinical trial designed to compare the effect of intensive lifestyle change or medication on delay of diabetes onset in a prediabetic population.2 The study ended in 2001 with the conclusion that intensive lifestyle change reduced diabetes risk by 58% and metformin medication by 31% over a period of 3 years.3 Participants continue to be followed in a long-term study: the Diabetes Prevention Program Outcomes Study (DPPOS)—designed to investigate longer-term complications of diabetes such as cardiovascular and microvascular outcomes (nephropathy, neuropathy, and diabetic retinopathy) over 10 years of follow-up. Starting in October 2005, DPPOS clinics began to fall under state legislature mandates to eliminate mercury from health-care facilities. With the understanding that eventually all mercury Sphygmomanometers will be replaced, the DPPOS study group investigated what effects such a conversion might have on the study's longitudinal blood pressure measurements. Although the published studies4-6 showed that Aneroid devices could be accurate, several issues remained unanswered in relation to clinical trial studies. These prior Aneroid validation studies were done by connecting Aneroid Sphygmomanometers to a reference unit and comparing the readings from the Aneroid to the static pressure measurements set at fixed points. In real clinical trials, sources of variation in blood pressure measurements could include participant factors such as arm circumferences, technician factors such as measurement technique or interaction with participants. All of the above may affect the accuracy of Aneroid models. In DPPOS 1−4 research staff collected measurements in each of 26 US clinics. To ensure the quality and consistency of our blood pressure data across clinics and over time, and to determine whether the shift to Aneroid manometers would cause a systematic shift in measured blood pressure, the study group designed and implemented a study of its selected Aneroid Sphygmomanometer.
Tracy Whittingto - One of the best experts on this subject based on the ideXlab platform.
-
evaluating the accuracy of an Aneroid Sphygmomanometer in a clinical trial setting
American Journal of Hypertension, 2009Co-Authors: Marinella Temprosa, Ronald J Prineas, Sarah E Fowle, Maria G Montez, Jane Ownfriday, Mary Lou Carrionpeterse, Tracy WhittingtoAbstract:The mercury Sphygmomanometer has historically served as the “gold” standard for measurement of blood pressure. Recently, because of environmental concerns about the disposal of mercury-contaminated medical waste and the risk of spills from mercury Sphygmomanometers, the mercury Sphygmomanometer is being phased out in clinical settings. In 1998, the Environmental Protection Agency and American Hospital Association agreed to eliminate mercury containing waste from the health-care industry by 2005 (ref. 1). In response, many institutions began switching from mercury to Aneroid Sphygmomanometers. The Diabetes Prevention Program was a controlled, multi-center clinical trial designed to compare the effect of intensive lifestyle change or medication on delay of diabetes onset in a prediabetic population.2 The study ended in 2001 with the conclusion that intensive lifestyle change reduced diabetes risk by 58% and metformin medication by 31% over a period of 3 years.3 Participants continue to be followed in a long-term study: the Diabetes Prevention Program Outcomes Study (DPPOS)—designed to investigate longer-term complications of diabetes such as cardiovascular and microvascular outcomes (nephropathy, neuropathy, and diabetic retinopathy) over 10 years of follow-up. Starting in October 2005, DPPOS clinics began to fall under state legislature mandates to eliminate mercury from health-care facilities. With the understanding that eventually all mercury Sphygmomanometers will be replaced, the DPPOS study group investigated what effects such a conversion might have on the study's longitudinal blood pressure measurements. Although the published studies4-6 showed that Aneroid devices could be accurate, several issues remained unanswered in relation to clinical trial studies. These prior Aneroid validation studies were done by connecting Aneroid Sphygmomanometers to a reference unit and comparing the readings from the Aneroid to the static pressure measurements set at fixed points. In real clinical trials, sources of variation in blood pressure measurements could include participant factors such as arm circumferences, technician factors such as measurement technique or interaction with participants. All of the above may affect the accuracy of Aneroid models. In DPPOS 1−4 research staff collected measurements in each of 26 US clinics. To ensure the quality and consistency of our blood pressure data across clinics and over time, and to determine whether the shift to Aneroid manometers would cause a systematic shift in measured blood pressure, the study group designed and implemented a study of its selected Aneroid Sphygmomanometer.